Patient perspectives on ipilimumab across the melanoma treatment trajectory Academic Article uri icon


MeSH Major

  • Family Health
  • Health Knowledge, Attitudes, Practice
  • Melanoma
  • Skin Neoplasms


  • Patients generally regarded ipilimumab positively despite the risk of unique toxicities and potential for delayed therapeutic responses; however, those with progression expressed uncertainty regarding whether taking ipilimumab was worthwhile. Physician communication practices and patient education regarding realistic expectations for therapeutic benefit as well as unique toxicities associated with ipilimumab should be developed so that patients can better understand the possible outcomes from treatment.

publication date

  • March 2017



  • Academic Article



  • eng

PubMed Central ID

  • PMC5651412

Digital Object Identifier (DOI)

  • 10.1007/s00520-017-3621-z

PubMed ID

  • 28247127

Additional Document Info

start page

  • 1

end page

  • 13